Navigation Links
Acid Test - Glaxo's Cervarix, and Merck's Gardasil, Compete

GlaxoSmithKline Plc, Europe's pharmaceutical giant, is finalizing its plan of action, to test its experimental// vaccine Cervarix against Merck & Co.'s Gardasil, in a bid to establish the most effective vaccine against cervical cancer.

The study, which will be conducted in the United States, will seek to evaluate the immune responses of women aged 18 to 26 years old, to two strains of the human papillomavirus. This virus is known to be the reason behind 70 percent of cervical cancers.

Glaxo has presented Cervarix to European regulators, while Gardasil received approval in the U.S. and Europe in 2006. Analyst Tim Anderson of Prudential Equity Group said, ``this is a very strategic and high stakes gamble by Glaxo that could have significant implications for both companies.''

Statistics show that cervical cancer is the second-most common cancer among women, with as many as 250,000 women dying every year to the disease. Both the vaccines in question comprise of vaccine boosters called adjuvants. Merck's Gardasil utilizes a conventional aluminum adjuvant, while Glaxo's Cervarix, uses a proprietary adjuvant named as AS04. Glaxo is confident of AS04’s effectiveness and that’s why the trial.

Brian Lortie, Glaxo's vice president of operations for the vaccine, said, ``we as a company think that the adjuvants differentiate the company. These are always risks that you take in clinical trials. We think there are some fundamental differences between these vaccines and that's why we're confident to begin the trial.''

Glaxo has decided to make the results of the trial public, irrespective of the brand that turns out to be the winner.


SA
'"/>




Page: 1

Related medicine news :

1. Daronrix, Glaxos Bird-flu Vaccine Approved by European Medicines Agency
2. Ranbaxy in Fray to Buy Mercks Generic Drugs Unit
3. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
4. Gardasil, a cervical cancer vaccine, hits the market
5. Botox Can Be a Competent Painkiller
6. Generic Products Compete With GlaxoSmithKline
7. Official Criticized For Not Recognizing the Competence of the Consultant Radiologist
8. Indian Americans Compete for the Prestigious Spelling Bee Contest
9. Two cloned mules, Compete In A Professional Race For The First Time Ever.
10. Sleep Deprivation can Affect Competent Decision-making
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: